Nabi-HB Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The nabi-hb market research report is one of a series of new reports that provides nabi-hb market statistics, including nabi-hb industry global market size, regional shares, competitors with a nabi-hb market share, detailed nabi-hb market segments, market trends and opportunities, and any further data you may need to thrive in the nabi-hb industry. This nabi-hb market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the prevalence of hepatitis B virus (HBV) infections, awareness of post-exposure prophylaxis, availability of healthcare facilities, support from advocacy groups, and an increasing aging population. Major trends in the forecast period include the availability of HBV vaccines, regulatory approvals and guidelines, advancements in biotechnology, shifts towards preventive medicine, and advancements in medical research.

The growing prevalence of hepatitis B is expected to drive the expansion of the nabi-hb market in the future. Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV), which can lead to chronic liver diseases and liver cancer. The increase in hepatitis B cases is driven by factors such as inadequate vaccination coverage, higher rates of unprotected sexual activity, the sharing of needles among drug users, and limited access to healthcare in high-risk regions. Nabi-HB plays a critical role in providing short-term protection against hepatitis B, especially in high-risk situations such as post-exposure prophylaxis and liver transplant procedures. According to the World Health Organization (WHO), there were an estimated 254 million people living with chronic hepatitis B in 2022, and 1.2 million new infections each year. Furthermore, hepatitis B caused around 1.1 million deaths globally in 2022. As the incidence of hepatitis B continues to rise, so does the demand for nabi-hb.

The increasing prevalence of chronic diseases is also contributing to the growth of the nabi-hb market. Chronic diseases are long-term conditions that require ongoing management, including treatment and preventive care. The rise in chronic diseases can be attributed to factors such as an aging population, unhealthy lifestyles (such as poor diets, lack of exercise, and smoking), environmental influences, and greater exposure to risk factors such as pollution and stress. Nabi-HB helps manage chronic diseases by providing passive immunity against hepatitis B virus (HBV) in individuals at high risk of exposure, preventing the development of chronic HBV infection and its long-term complications, such as liver cirrhosis or liver cancer, which are more common in people with chronic viral infections. For example, Liver Cancer UK reported in October 2024 that new cases of liver cancer rose by 8,085 in 2022, with 4,700 cases in males and 3,385 in females. The growing incidence of chronic diseases is a major driver of the nabi-hb market.

The expanding aging population is another significant factor driving the growth of the nabi-hb market. An aging population refers to an increasing proportion of individuals aged 65 and older within a population, often resulting from longer life expectancy and lower birth rates. The number of older adults is rising due to advancements in healthcare, improved living conditions, and greater life expectancy, combined with a decline in birth rates. Nabi-HB offers protection for the aging population by providing passive immunity against the hepatitis B virus, reducing the risk of chronic infections and associated complications, which are more common among older adults with weakened immune systems. This helps support healthier aging and reduce long-term healthcare costs. According to the World Health Organization, by 2030, one in six people worldwide will be aged 60 or older, with the population in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and above is expected to double to 2.1 billion, while the number of people aged 80 and older is projected to triple between 2020 and 2050, reaching 426 million. As the aging population grows, the demand for nabi-hb is expected to rise as well.

The key company operating in the nabi-hb market is ADMA Biologics Inc.

North America was the largest region in the nabi-hb market in 2024. The regions covered in nabi-hb report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nabi-hb market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Nabi-HB is a human hepatitis B immune globulin (HBIG) used for post-exposure prevention of hepatitis B virus (HBV) infection, especially in individuals who have been exposed to the virus through needlesticks, surgeries, or other forms of contact. It provides passive immunity by delivering antibodies against HBV, offering temporary protection until the body can develop its own immune response.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Nabi-HB is primarily indicated for post-exposure prophylaxis and prevention in high-risk groups. Post-exposure prophylaxis involves administering preventive treatment after potential exposure to a disease, such as hepatitis B, to lower the risk of infection. It is available in injectable form and pre-filled syringes, and is distributed through hospitals, specialty clinics, public health agencies, and pharmacies. It is used by both infants and adults.

The nabi-hb market consists of sales of combination vaccines, immunoglobulins, flu vaccines and pneumococcal vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.